Clinical Trials Logo
  1. Home
  2. Hematological Disease
  3. NCT00820508

Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies — CHR-2845-001  

Lymphoid Malignancies Clinical Trial

Official title:
A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-2845, in Patients With Advanced or Treatment Refractory Haematological Diseases or Lymphoid Malignancies

Clinical Trial Summary

The purpose of this study is to determine whether the histone deacetylase inhibitor CHR-2845 is tolerated in patients with haematological diseases and lymphoid malignancies.

Clinical Trial Description

CHR-2845 is a novel type of histone deacetylase inhibitor (HDACi) for use in cancer that, in addition to having broad ranging anti-proliferative activity against transformed cells, is designed to have an increased therapeutic window against diseases which involve cells of the monocyte-macrophage lineage. There are several HDACi's in clinical development and one, SAHA (Vorinostat, Zolinza®), has recently been approved for use in the treatment of cutaneous T-cell lymphoma. CHR-2845 is a cell-permeant ester that is metabolised to give an active acid, CHR-2847, which selectively accumulates in monocytes and macrophages. This results in a 20-100 fold increase in anti-proliferative potency of CHR-2845 for monocytic over non-monocytic tumour cells. This selectivity should lead to an increased therapeutic window in haematological malignancies involving cells of the monocyte lineage (AML M4, AML M5 and CMML). In addition, there is increasing evidence that monocytes and macrophages associated with some haematological tumours (tumour-associated macrophages (TAMs)) are involved in supporting the growth and spread of the tumour. This clinical trial will focus on haematological and lymphoid malignancies with the intention of evaluating the safety and tolerability of CHR-2845. Additionally it will compare response in patients where monocytes/macrophages are important disease drivers, with the response in other patients. This will allow an early determination of the potential improvement in therapeutic window afforded by the monocyte/macrophage directed HDACi activity. ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00820508
Study type Interventional
Source Chroma Therapeutics
Contact
Status Completed
Phase Phase 1
Start date December 2008
Completion date July 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00383994 - Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation Phase 1
Terminated NCT01013818 - A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies Phase 1
Recruiting NCT04329728 - The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies Phase 1/Phase 2
Terminated NCT01998035 - Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT01705847 - A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies Phase 1
Completed NCT00406809 - A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies Phase 1/Phase 2
Terminated NCT02739360 - Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820 Phase 4
Terminated NCT00992732 - Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders Phase 2
Active, not recruiting NCT02452697 - Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT Phase 2
Not yet recruiting NCT06047886 - CD34 Selection Using the Automated CliniMACS Prodigy Phase 1
Completed NCT02181478 - Intra-Osseous Co-Transplant of UCB and hMSC Early Phase 1
Terminated NCT01596127 - Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System Phase 1/Phase 2
Recruiting NCT05371054 - Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00529438 - RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies Phase 1
Completed NCT01435447 - Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies Phase 2
Completed NCT00508807 - RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies Phase 1
Completed NCT02091063 - ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2